11:51 AM EST, 11/05/2025 (MT Newswires) -- Hinge Health's ( HNGE ) 2026 selling season is tracking ahead of prior year performance, with majority of client additions in Q4 scheduled to launch in early 2026, Morgan Stanley said in Wednesday note.

Noting the company's Q3 results, Morgan Stanley said that the company's adjusted earnings before interest and taxes of $30.4 million was "meaningfully" above Wall Street estimate of $19 million, as investment in automation and artificial intelligence are driving "meaningful operating leverage".

Morgan Stanley also increased its 2025, 2026, and 2027 revenue estimates by 4%, 5%, and 5% respectively, and EBIT estimates by 33%, 25%, and 21%, respectively.

Morgan Stanley maintained its overweight rating on the stock and raised its price target to $72 from $67.

Price: 46.86, Change: -6.58, Percent Change: -12.31